Richard K. Prins net worth and biography

Richard Prins Biography and Net Worth

Richard Prins has served as a member of our Board of Directors since 2002. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp. He has 26 years of experience in all aspects of corporate finance and has participated directly in more than 150 transactions with both private and public companies across a number of industries in North America, Europe, and Asia. Mr. Prins was the Director of Investment Banking for Ferris, Baker Watts, Inc. (“FBW”), from 1996 until June of 2008 when FBW was acquired by Royal Bank of Canada. At FBW, he managed all of the firm's industry groups and product offerings including public offerings, mergers and acquisitions, private placements, restructurings, as well as other corporate advisory services activities. He was also responsible for executing a variety of financial and strategic transactions. Mr. Prins served as a consultant to Royal Bank of Canada Capital Markets through December 2008 to facilitate the post-acquisition transition. Prior to FBW, he was a Managing Director for eight years at Crestar Bank (now SunTrust Bank) in charge of Mergers and Acquisitions. Currently Mr. Prins is a private investor and involved in various charitable organizations. Also, he currently volunteers as acting head of US Operations for Advancing Native Missions and on the boards of directors of India Globalization Capital and Hilbert Technology. Mr. Prins received a B.A. in Liberal Arts from Colgate University and an M.B.A. from Oral Roberts University.

What is Richard K. Prins' net worth?: The estimated net worth of Richard K. Prins is at least $866,290.53 as of December 9th, 2024. Mr. Prins owns 30,471 shares of Amphastar Pharmaceuticals stock worth more than $866,291 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Prins may own. Learn More about Richard K. Prins' net worth.
How do I contact Richard K. Prins?: The corporate mailing address for Mr. Prins and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at jasons@amphastar.com. Learn More on Richard K. Prins' contact information.
Has Richard K. Prins been buying or selling shares of Amphastar Pharmaceuticals?: Richard K. Prins has not been actively trading shares of Amphastar Pharmaceuticals during the past quarter. Most recently, Richard K. Prins sold 10,000 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $43.77, for a transaction totalling $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares of the company's stock, valued at $1,333,715.67. Learn More on Richard K. Prins' trading history.
Who are Amphastar Pharmaceuticals' active insiders?: Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amphastar Pharmaceuticals?: In the last year, insiders at the sold shares 16 times. They sold a total of 88,243 shares worth more than $3,963,385.79. The most recent insider tranaction occured on March, 4th when CFO William J Peters sold 4,231 shares worth more than $116,521.74. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.
Information on this page was last updated on 3/4/2025.

Richard K. Prins Insider Trading History at Amphastar Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/9/2024	Sell	10,000	$43.77	$437,700.00	30,471
11/12/2024	Sell	5,000	$48.80	$244,000.00	31,471
8/12/2024	Sell	17,101	$43.07	$736,540.07	33,971
11/17/2023	Sell	4,000	$55.86	$223,440.00	31,895
11/13/2023	Sell	5,000	$52.50	$262,500.00	35,895
8/18/2023	Sell	2,000	$52.50	$105,000.00	40,895
5/12/2023	Sell	5,000	$42.06	$210,300.00	47,342
12/10/2021	Sell	5,291	$21.36	$113,015.76
11/22/2021	Sell	5,000	$21.22	$106,100.00
6/7/2021	Sell	5,000	$18.70	$93,500.00	140,741
5/11/2021	Sell	15,827	$18.90	$299,130.30	54,987
8/11/2020	Sell	6,000	$20.33	$121,980.00	39,160
8/26/2019	Sell	7,500	$22.59	$169,425.00	43,191
8/23/2019	Sell	3,882	$22.58	$87,655.56	43,191
8/13/2019	Sell	10,000	$20.78	$207,800.00	49,309
12/14/2018	Sell	1,616	$20.65	$33,370.40	33,818
11/29/2018	Sell	5,000	$20.50	$102,500.00
11/14/2018	Sell	5,000	$20.23	$101,150.00	40,434
8/14/2018	Sell	10,000	$17.82	$178,200.00
3/15/2018	Sell	16,598	$19.90	$330,300.20	45,442
8/15/2017	Sell	10,000	$14.81	$148,100.00	33,844
8/14/2017	Sell	5,000	$14.80	$74,000.00	33,844
6/9/2017	Sell	10,000	$17.07	$170,700.00	28,844
5/11/2017	Sell	7,500	$15.43	$115,725.00	30,500
8/18/2016	Sell	3,086	$19.62	$60,547.32	26,000
8/11/2016	Sell	13,993	$18.03	$252,293.79	31,681
6/13/2016	Sell	7,500	$15.94	$119,550.00	29,086
5/17/2016	Sell	3,200	$13.56	$43,392.00	23,000
3/17/2016	Sell	2,400	$11.25	$27,000.00	26,200
8/18/2015	Sell	9,100	$14.66	$133,406.00
8/17/2015	Sell	5,400	$14.70	$79,380.00	35,722
5/22/2015	Sell	29,452	$14.77	$435,006.04
5/19/2015	Sell	3,000	$14.94	$44,820.00
8/18/2014	Buy	4,000	$10.02	$40,080.00

See Full Table

Richard K. Prins Buying and Selling Activity at Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Today's Range

Now: $28.43

$28.23

$28.71

50 Day Range

MA: $31.07

$26.24

$37.12

2 Week Range

Now: $28.43

$25.89

$53.96

Volume

386,842 shs

Average Volume

438,844 shs

Market Capitalization

$1.35 billion

P/E Ratio

9.48

Dividend Yield

N/A

Beta

0.77